Your browser doesn't support javascript.
loading
Association Between Patient Survival and Clinician Variability in Treatment Rates for Aortic Valve Stenosis.
Brennan, J Matthew; Lowenstern, Angela; Sheridan, Paige; Boero, Isabel J; Thourani, Vinod H; Vemulapalli, Sreekanth; Wang, Tracy Y; Liska, Otto; Gander, Stuart; Jager, Jason; Leon, Martin B; Peterson, Eric D.
Afiliação
  • Brennan JM; Duke Clinical Research Institute Duke University School of Medicine Durham NC.
  • Lowenstern A; Duke Clinical Research Institute Duke University School of Medicine Durham NC.
  • Sheridan P; Department of Family Medicine and Public Health University of California, San Diego School of Medicine San Diego CA.
  • Boero IJ; Boston Consulting Group Boston MA.
  • Thourani VH; Boston Consulting Group Boston MA.
  • Vemulapalli S; Department of Cardiovascular Surgery Piedmont Heart Institute Atlanta GA.
  • Wang TY; Duke Clinical Research Institute Duke University School of Medicine Durham NC.
  • Liska O; Duke Clinical Research Institute Duke University School of Medicine Durham NC.
  • Gander S; Boston Consulting Group Boston MA.
  • Jager J; Boston Consulting Group Boston MA.
  • Leon MB; Boston Consulting Group Boston MA.
  • Peterson ED; Columbia University Irving Medical Center and New York Presbyterian Hospital New York NY.
J Am Heart Assoc ; 10(16): e020490, 2021 08 17.
Article em En | MEDLINE | ID: mdl-34387116
Background Patients with symptomatic severe aortic stenosis (ssAS) have a high mortality risk and compromised quality of life. Surgical/transcatheter aortic valve replacement (AVR) is a Class I recommendation, but it is unclear if this recommendation is uniformly applied. We determined the impact of managing cardiologists on the likelihood of ssAS treatment. Methods and Results Using natural language processing of Optum electronic health records, we identified 26 438 patients with newly diagnosed ssAS (2011-2016). Multilevel, multivariable Fine-Gray competing risk models clustered by cardiologists were used to determine the impact of cardiologists on the likelihood of 1-year AVR treatment. Within 1 year of diagnosis, 35.6% of patients with ssAS received an AVR; however, rates varied widely among managing cardiologists (0%, lowest quartile; 100%, highest quartile [median, 29.6%; 25th-75th percentiles, 13.3%-47.0%]). The odds of receiving AVR varied >2-fold depending on the cardiologist (median odds ratio for AVR, 2.25; 95% CI, 2.14-2.36). Compared with patients with ssAS of cardiologists with the highest treatment rates, those treated by cardiologists with the lowest AVR rates experienced significantly higher 1-year mortality (lowest quartile, adjusted hazard ratio, 1.22, 95% CI, 1.13-1.33). Conclusions Overall AVR rates for ssAS were low, highlighting a potential challenge for ssAS management in the United States. Cardiologist AVR use varied substantially; patients treated by cardiologists with lower AVR rates had higher mortality rates than those treated by cardiologists with higher AVR rates.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Avaliação de Processos e Resultados em Cuidados de Saúde / Estenose da Valva Aórtica / Padrões de Prática Médica / Implante de Prótese de Valva Cardíaca / Substituição da Valva Aórtica Transcateter / Cardiologistas Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Avaliação de Processos e Resultados em Cuidados de Saúde / Estenose da Valva Aórtica / Padrões de Prática Médica / Implante de Prótese de Valva Cardíaca / Substituição da Valva Aórtica Transcateter / Cardiologistas Idioma: En Ano de publicação: 2021 Tipo de documento: Article